Anti-GBM antibody disease (Goodpasture disease) research hub

A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in the treatment of severe anti-GBM antibody disease (Goodpasture disease)

This study is testing a new medicine, Idefirix, for a rare kidney disease called Goodpasture disease. Researchers want to see if Idefirix, along with usual care, helps kidney function better than usual care alone over six months.